“The criteria for coverage of hepatitis C treatments is being expanded in a phased approach. Coverage will be further extended to all patients regardless of severity of disease or genotype within the next 12 months.” –Ontario Public Drug Programs
“We look forward to the day that all criteria are lifted and all people living with hep C can access treatment, regardless of disease and genotype.” -Pacific Hepatitis C Network
Effective February 28, 2017, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.
• Harvoni (ledipasvir/sofosbuvir)
• Sovaldi (sofosbuvir)
• Epclusa (sofosbuvir/velpatasvir)
• Zepatier (elbasvir/grazoprevir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir)
• Ibavyr (ribavirin)
The above drugs will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as Limited Use (LU) benefits.
Health care providers are advised to refer to the Formulary for information about the specific reimbursement criteria applicable to each of the funded hepatitis C drugs.
The range of funded hepatitis C drug products will enable funding consideration for patients with most of the common or mixed genotypes in Ontario when the specified criteria are met.
The full details of the LU criteria will be also be posted in the February 2017 monthly Formulary update at:
Please call ODB Pharmacy Help Desk at: 1-800-668-6641
For all other Health Care Providers and the Public:
Please call ServiceOntario, Infoline at 1-866- 532- 3161 TTY 1-800-387 -5559. In Toronto, TTY 416- 327 -4282